Honigman Represents Decoy Therapeutics in Warrant Inducement Transaction

Honigman represented Decoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D‑MAVs™), in connection with a warrant inducement transaction with an existing institutional investor involving the exercise of 1,184,434 Series B Milestone Warrants and the issuance of new warrants in a private placement.

The exercise of the existing warrants resulted in approximately $3.85 million in gross proceeds before deducting placement agent fees and other transaction expenses. In connection with the transaction, the investor received new unregistered warrants to purchase up to 2,368,868 shares of Decoy's common stock in a private placement. Curvature Securities LLC acted as the sole placement agent in connection with the transaction.

The Honigman team was led by Corporate Partners Jeffrey Kuras and Michael J. Rosenberg, with support from Associate Isaac (Yitzhak) Pasha.